Have a personal or library account? Click to login

Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes

Radiology and Oncology
Volume 56 (2022): Issue 4 (December 2022)
By:
Open Access
|Dec 2022

Figures & Tables

Figure 1

The principle of adoptive cellular immunotherapy. CAR = chimeric antigen receptor; TCR = T-cell receptor
The principle of adoptive cellular immunotherapy. CAR = chimeric antigen receptor; TCR = T-cell receptor

Figure 2

Schematics of the basic CAR architecture. CAR = chimeric antigen receptor; scFv = single-chain variable fragment
Schematics of the basic CAR architecture. CAR = chimeric antigen receptor; scFv = single-chain variable fragment

Figure 3

Challenges of cellular immunotherapy with chimeric antigen receptor (CAR) T cells.
Challenges of cellular immunotherapy with chimeric antigen receptor (CAR) T cells.
DOI: https://doi.org/10.2478/raon-2022-0049 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 409 - 419
Submitted on: Oct 19, 2022
Accepted on: Oct 27, 2022
Published on: Dec 13, 2022
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
chimeric antigen receptor,
adoptive cell therapy,
cancer,
cellular immunotherapy,
gene-engineered immune cells
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2022 Anze Smole, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 56 (2022): Issue 4 (December 2022)Next article